Treatment of Dry Eye from Laser-Assisted In Situ Keratomileusis With Recombinant Human Nerve Growth Factor (Cenegermin)

Purpose: To describe 2 patients with neurotrophic keratitis after laser-assisted in situ keratomileusis surgery who were treated with recombinant human nerve growth factor (cenegermin) and the treatment course. Methods: Case series. Results: After an 8 week course of cenegermin, there was an improvement in visual acuity, corneal sensitivity, and ocular surface staining. However, these effects were short lived, and the disease regressed at subsequent follow-up visits. Conclusions: Although recombinant human nerve growth factor seems to be effective in short term for neurotrophic keratitis secondary to laser-assisted in situ keratomileusis surgery, alternative dosing for patients with this patient population should be considered to achieve long-lasting resolution.